Research Study

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Principal Investigator 
Raewyn Broady

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
ClinicalTrials.gov# 
NCT01877655
Status 
Closed to Recruitment
Study Start/End 
Oct 15, 2014 to Dec 31, 2018
Locations 
Vancouver General Hospital
Name/Title 
Tania Haqq, Study Coordinator
Phone 
604-875-4111 ext.67409
Email Address 
thaqq@bccancer.bc.ca
Purpose of Study 

The purpose of the study is to determine if overall mortality is affected one year after a hematopoietic stem cell transplant (HCT) in patients given a vaccine to prevent cytomegalovirus (CMV).  Safety of ASP0113 in subjects undergoing allogeneic HCT will also be evaluated.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.